Email this article 
An accelerated hypofractionated radiotherapy regimen in patients after organ-sparing surgery for stages I–IIA breast cancer
- Authors: Gladilina I.A.1, Klepper L.Y.2, Efimkina Y.V.1, Vysotskaya I.V.3, Petrovskiy A.V.1, Kozlov O.V.1, Chernykh M.V.1, Voronchikhina E.Y.3, Makarov E.S.1, Ivanova A.V.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
- Central Economics and Mathematics Institute, Russian Academy of Sciences
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- Issue: Vol 12, No 3 (2016)
- Pages: 17-22
- Section: MAMMOLOGY. ORIGINAL ARTICLE
- Published: 23.11.2016
- URL: https://ojrs.abvpress.ru/ojrs/article/view/503
- DOI: https://doi.org/10.17650/1994-4098-2016-12-3-17-22
- ID: 503
Cite item
Full Text
Abstract
Objective: to assess the results of accelerated hypofractionated radiotherapy and to comparatively analyze it with the standard radiotherapy in patients with stages I–IIA breast cancer (BC) after organ-sparing surgery.
Materials and methods. A total of 203 patients with stages I–IIA BC underwent radiotherapy after organ-sparing surgery. A control group of 91 patients received the standard radiotherapy (the single focal dose (SFD) was 2 Gy 5 times a week, 25 fractions; the total focal dose (TFD) was 50 Gy for 5 weeks). A study group of 112 patients had accelerated hypofractionated radiotherapy (SFD 3 Gy 5 times a week, 13 fractions; TFD 39 Gy for 2.3 weeks).
Results. Local recurrences were not detected in any patient after the hypofractionated radiotherapy regimen and were diagnosed in 3.3 % of the patients after the standard regimen. There were no statistically significant differences between the groups in 5-year overall and relapsefree survival rates. Further observation revealed a statistically significant difference in 6-year overall survival rates in the study and control groups: 99.1 and 70.4 %, respectively (p ≤ 0.046). The 6-year relapse-free survival rates in patients who had received the accelerated hypo-fractionated radiotherapy regimen were also significantly higher than in those who had the standard radiotherapy regimen: 97.9 and 71.3 %, respectively (p ≤ 0.043). The rate of post-radiation normal tissue damages after the hypofractionated radiotherapy regimen was significantly lower (15.2 %) than that after the standard regimen (27.5 %). Good and excellent cosmetic results of treatment were achieved in most (95.1 %) patients and did not differ in their frequency after different radiotherapy regimens.
Conclusion. The accelerated hypofractionated radiotherapy regimen showed a high efficiency and a favorable toxicity profile in patients with stages I–IIA BC.
About the authors
I. A. Gladilina
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Author for correspondence.
Email: 0152@mail.ru
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
L. Ya. Klepper
Central Economics and Mathematics Institute, Russian Academy of Sciences47 Nakhimovskiy Prospect, Moscow, 117418 Russian Federation
Yu. V. Efimkina
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
I. V. Vysotskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia2 Build. 4, Bol’shaya Pirogovskaya St., Moscow, 119991 Russian Federation
A. V. Petrovskiy
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
O. V. Kozlov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
M. V. Chernykh
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
E. Yu. Voronchikhina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia2 Build. 4, Bol’shaya Pirogovskaya St., Moscow, 119991 Russian Federation
E. S. Makarov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
A. V. Ivanova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
References
Supplementary files
